Focus Partners Advisor Solutions LLC Sells 3,979 Shares of Edwards Lifesciences Co. (NYSE:EW)

Focus Partners Advisor Solutions LLC cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 48.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,194 shares of the medical research company's stock after selling 3,979 shares during the period. Focus Partners Advisor Solutions LLC's holdings in Edwards Lifesciences were worth $310,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in EW. Crowley Wealth Management Inc. bought a new stake in Edwards Lifesciences in the 4th quarter worth about $26,000. Millstone Evans Group LLC bought a new stake in Edwards Lifesciences in the 4th quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences in the 4th quarter worth about $30,000. Catalyst Capital Advisors LLC bought a new stake in Edwards Lifesciences in the 4th quarter worth about $54,000. Finally, SBI Securities Co. Ltd. bought a new stake in Edwards Lifesciences in the 4th quarter worth about $62,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Trading Down 0.0%

Shares of NYSE:EW traded down $0.01 on Friday, hitting $77.72. The company had a trading volume of 2,574,193 shares, compared to its average volume of 5,157,842. The firm's 50-day simple moving average is $73.22 and its two-hundred day simple moving average is $72.33. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $45.59 billion, a price-to-earnings ratio of 11.20, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Edwards Lifesciences's revenue was up 6.2% on a year-over-year basis. During the same period last year, the company posted $0.66 EPS. Equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 400 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the sale, the vice president now owns 22,588 shares in the company, valued at approximately $1,569,414.24. The trade was a 1.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction on Wednesday, March 26th. The stock was sold at an average price of $70.87, for a total transaction of $797,287.50. Following the completion of the sale, the chief financial officer now owns 30,387 shares in the company, valued at $2,153,526.69. This represents a 27.02% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 56,442 shares of company stock worth $4,025,799. 0.34% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Canaccord Genuity Group upped their price objective on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research report on Friday, April 25th. Citigroup reiterated a "buy" rating and issued a $95.00 target price (up from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Morgan Stanley boosted their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a research note on Wednesday, February 12th. Robert W. Baird boosted their target price on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday, April 24th. Finally, Barclays boosted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of "Hold" and a consensus target price of $80.20.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.